Antibiotic Treatment for Hidradenitis Suppurativa

Introduction to Treatment

The American Academy of Dermatology recommends clindamycin 300 mg orally twice daily plus rifampicin 300-600 mg orally once or twice daily for 10-12 weeks as first-line antibiotic therapy for moderate Hidradenitis Suppurativa, achieving response rates of 71-93% 1, 2, 3

For mild disease, the American Academy of Dermatology suggests starting with topical clindamycin 1% solution or gel applied twice daily to all affected areas for 12 weeks as first-line therapy 1, 2, 4
For moderate disease, the first-line systemic antibiotic is clindamycin 300 mg orally twice daily plus rifampicin 300-600 mg orally once or twice daily for 10-12 weeks, achieving response rates of 71-93% 1, 2, 3, 5
The American Academy of Dermatology recommends against using tetracyclines as first-line for Hurley Stage II with abscesses or deep inflammatory nodules, as they have minimal effect on these lesions 2, 3

For pediatric patients ≥8 years old requiring systemic antibiotics, the American Academy of Dermatology recommends doxycycline 100 mg once or twice daily or clindamycin 300 mg twice daily plus rifampicin 300 mg twice daily for 10-12 weeks 2, 5
For patients with a history of malignancy, doxycycline is the safest choice with strong evidence of safety (strong recommendation, moderate quality evidence) 5

The American Academy of Dermatology recommends reassessing treatment response at 12 weeks using pain VAS score, inflammatory lesion count, number of flares, and quality of life (DLQI) 1, 2, 3, 4
Treatment with clindamycin-rifampicin typically lasts 10-12 weeks and can be repeated intermittently 1, 2, 3

The American Academy of Dermatology advises against using topical clindamycin alone for Hurley Stage II, as it only reduces superficial pustules, not inflammatory nodules or abscesses 3
The American Academy of Dermatology recommends avoiding long-term antibiotic use without treatment breaks to reduce antimicrobial resistance risk 1, 2, 3

The American Academy of Dermatology suggests smoking cessation referral, as tobacco use worsens outcomes 2, 4
The American Academy of Dermatology recommends weight management referral if BMI is elevated, as obesity is associated with worse disease 2, 4
The American Academy of Dermatology advises pain management with NSAIDs for symptomatic relief 2, 4